Merus had a standout start this month. Shortly after landing a long-anticipated commercialization partner for its zenocutuzumab, the drug has achieved FDA approval, becoming the first therapy to target cancers with a neuregulin 1 (NRG1) gene fusion.
The FDA granted accelerated approval to the drug, now marketed as BIZENGRI, for treating NRG1 fusion-positive non-small cell lung cancer (NSCLC) and NRG1 fusion-positive pancreatic adenocarcinoma in patients whose disease has progressed after previous systemic therapy.
NRG fusions have been identified in over ten types of solid tumors, indicating they represent a potential target for a wide, tumor-agnostic therapeuti...
